Drug Profile
ZED 1227
Alternative Names: TAK-227; ZED-101; ZED-1227Latest Information Update: 15 Oct 2023
Price :
$50
*
At a glance
- Originator Zedira GmbH
- Developer Dr Falk Pharma; Takeda; University Medical Center of the Johannes Gutenberg University Mainz; Zedira GmbH
- Class Hepatoprotectants; Imidazoles; Pyridines; Small molecules
- Mechanism of Action Transglutaminase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Coeliac disease; Non-alcoholic fatty liver disease
Most Recent Events
- 26 Jun 2023 Takeda completes a phase I trial in Coeliac diseases in USA (PO) (NCT05818956)
- 26 Jun 2023 Takeda completes a phase I pharmacokinetics trial (In volunteers, In adults) in USA (NCT05818956)
- 25 May 2023 Phase-I clinical trials in Coeliac disease (In volunteers) in USA (PO)